Abstract: [Abstract] Objective   To examine the effects of genetic polymorphisms in GSTM1, GSTT1 and GSTP1(rs1695) genes on hematologic toxicities of breast cancer patients receiving Anthracycline/Paclitaxel-based chemotherapy. Methods   The multiply PCR technique and High Resolution Melting method were used to examine 3 gene polymorphsim in 252 female breast cancers. Results   The GSTP1(rs1695) AG/GG genotype was a risk factor for Ⅲ-Ⅳ degree of neutrophil toxicity when patients received Paclitaxel-based chemotherapy and Anthracycline-Paclitaxel-based chemotherapy(OR=6.111, 95% CI:1.526~24.469, P<0.05 and OR=9.257, 95% CI:2.903-29.522, P<0.01), while there were no statistic difference on Ⅲ-Ⅳ degree hematologic toxicities rates between GSTM1(+) and GSTM1(-), GSTT1(+) and GSTT1(-) patients receiced Paclitaxel-based chemotherapy and Anthracycline-Paclitaxel-based chemotherapy(P>0.05); there was still no statistic difference on Ⅲ-Ⅳdegree hematologic toxicities rates between GSTM1(+) and GSTM1(-), GSTT1(+) and GSTT1(-), GSTP1AA and GSTP1AG/GG patients receiced Anthracycline-based chemotherapy(P>0.05). Conclusion   The genetic polymorphisms in GSTP1(rs1695) can be a gene markers for forecasting the chemotherapy neutropenia toxicities of breast cancer patients receiving Paclitaxel-based chemotherapy.

Key words: breast neoplasms, glutathione transferase, polymorphism, genetic, Polymerase chain reaction, chemotherapy hematologic toxicities, High Resolution Melting., 抗肿瘤联合化疗方案